Many age-related chronic diseases are associated with changes in DNA methylation, including cardiovascular disease. Cardiovascular diseases are a group of diseases that affect the structure and function of the heart or blood vessels, including atherosclerosis, heart failure, myocardial infarction, and hypertension. In studies on cardiovascular disease risk, DNA methylation levels have been found to correlate with their predisposing factors. Therefore, the discovery and identification of DNA methylation at specific CpG sites may be a source for the development of biomarkers for cardiovascular diseases. With a unique technology platform, CD BioSciences can provide DNA methylation biomarker discovery services for aging-related cardiovascular diseases.
CD BioSciences is committed to being a professional partner you can trust to provide you with first-class technical services to accelerate your DNA methylation biomarker discovery projects and maximize your project applications. If you have any needs, you can contact us and we will solve your doubts and provide detailed information.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.